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Journal of Investigative Dermatology (2016) 136, 869e872; doi:10.1016/j.jid.2015.12.031Xeroderma pigmentosum (XP) is a
rare inherited disorder of DNA repair.
Affected individuals cannot repair
ultraviolet radiation (UVR)einduced
DNA damage, resulting in an increased
skin cancer risk (Bradford et al., 2011),
severe sunburn in approximately
50% of patients (Sethi et al., 2013),
and progressive neurodegeneration in
approximately 30% (Kraemer et al.,
1987; Totonchy et al., 2013). XP can
result from defects in any of eight genes
(XPAeXPG and POLH). XPAeXPG are
involved in nucleotide excision repair
(NER) of DNA damage (Cleaver et al.,
2009).
Xeroderma pigmentosum comple-
mentation group A (XP-A) patients
usually have a severe phenotype, with
exaggerated sunburn and early onset
of progressive neurodegeneration,
which results in death, usually in the
second or third decade (Anttinen
et al., 2008). XPA protein is required
for damage verification in the NER
pathway. More than 20 different mu-
tations have been identified in the XPA
gene (States et al., 1998; Takahashi
et al., 2010). Many of the reportedcases come from Japan because of
a founder mutation (c.390-1G>C)
carried by 1% of the Japanese popu-
lation (Hirai et al., 2006; Satokata
et al., 1990). This mutation results
in abnormal splicing of mRNA and
subsequent production of truncated,
nonfunctioning XPA protein and the
typically severe clinical phenotype.
Although a diagnosis of XP-A has
usually been associated with a poor
prognosis, a number of XP-A patients
undergoing long-term follow-up at the
UK National XP Clinic have a surpris-
ingly mild phenotype. To examine
this finding further, a detailed
genotype-phenotype study in this
cohort was conducted. Neurological
analysis included audiometry, nerve
conduction studies, brain magnetic
resonance imaging and neuro-
psychometric evaluations. Informed
written consent was obtained from all
patients. The study was performed in
accordance with protocols approved
by the Research Ethics Committee of
Guy’s and St. Thomas’ Hospitals NHS
Foundation Trust, London (reference
12/LO/0325).Nineteen of 90 patients being studied
at the UK National XP clinic were
assigned to complementation group
A (Table 1). Twelve of these patients,
from eight consanguineous families,
displayed a mild XP-A phenotype with
no ocular surface disease, delayed
onset or lack of skin cancer, and normal
neurological and neuropsychometric
evaluations (Figure 1aeh). Mean age
at assessment was 32 years (range
6e79 years) and mean age at clinical
diagnosis was 26 years (range 4e46
years), significantly higher than in the
more severely affected XP-A group of
patients, who showed progressive neu-
rodegeneration presenting as develop-
mental delay and cognitive impairment,
sensorineural hearing loss, micro-
cephaly, neuropathy, and cerebellar
signs (Table 1). Remarkably, one of the
patients, XP1CB, is aged 79 years
without any XP-related neurological
problems. He spent the first 30 years of
his life in India working mostly out-
doors and was only diagnosed clini-
cally at age 46 years. These 12 patients
all were homozygous for the mutation
c.555þ8A>G, which previously was
reported by Sidwell et al. (2006) in a
61-year-old Punjabi woman with no
neurological problems. All 12 patients
included in this study, as well as the
case described by Sidwell et al., origi-
nate from a 950-km stretch of landwww.jidonline.org 869
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Afghanistan borders (Figure 1i), sug-
gesting a founder effect present in this
population.
The c.555þ8A>G mutation at the
eighth nucleotide of intron 4 gener-
ates a new splice donor site and
results in aberrant splicing of intron 4
and nonfunctional, truncated XPA
protein. However, there is a small
amount of normally spliced mRNA
(Sidwell et al., 2006), which results
in production of residual normal XPA
protein detectable in immunoblots
(Figure 1j). Comparison of the upper
XPA band in lanes 9e12 with the
calibration in lanes 1e6 suggests that
50-mg extract from the mild XP-A
cells has the same amount of (or
less) XPA protein as 2.5-mg normal
extract (lane 2), indicating the pres-
ence of <5% of the normal level of
XPA protein in the mild XP-A cells.
In contrast, no protein is detectable
in the XP-A null cell line XP15BR
(lanes 1 and 13). This residual protein
carries out NER, consistent with
the 5e15% of normal unscheduled
DNA synthesis found in these pa-
tients (Figure 1k). This most likely
explains their normal neurological
phenotype. It has been shown that
low levels of XPA protein, transfected
into XPA-deficient cells, are able to
significantly protect against DNA
damage (Muotri et al., 2002).
Interestingly, the sunburn reactions
in this group are variable, even though
all patients are of similar ethnicity. This
may be explained by the fact that the
very small amount of functioning XPA
protein may not be sufficient to repair
the high level of photoproduct accu-
mulation after sun exposure, resulting
in moderate sunburn severity. However,
endogenous neurological damage is
likely to be generated continually at
a low rate so that the low level of
functioning XPA protein may be suffi-
cient to repair the damage as it occurs,
resulting in a normal neurological
phenotype.
A handful of other XP-A patients with
mild phenotype have been reported in
the literature, although none as mild as
our cohort. Four middle-aged Japanese
XP-A patients presented with late-onset
neurological impairment and moderate
sunburn reactions, without develop-
ment of skin cancer (Takahashi et al.,
Figure 1. Face views of mild xeroderma pigmentosum complementation group A (XP-A) patients and map of origins, immunoblots of protein extracts
probed with monoclonal antibody to XPA protein, and measurement of UDS in mild XP-A and control cell lines. (a) XP103BR: Seven-year-old girl with a few
facial lentigines (distantly related to patients shown in eeg). (b) XP53BR: Eighteen-year-old man who presented with sunburn lasting 1 week and increased
lentigines at exposed sites. (c, d) XP2PR, XP1PR: Two siblings aged 32 and 35 years, respectively, who developed facial lentigines at age 2 years (distantly
related to patients shown in e-g). (eeg) XP89BR-S, XP88BR, XP89BR: Three siblings, currently aged 34, 36, and 43 years, respectively, who presented with
increased facial lentigines and easy sunburn. (h) XP1CB: Seventy-nineeyear-old man who developed lentigines at exposed sites at age 6 years. Of the seven
other siblings in his family, four have XP. Until 30 years of age he had worked outdoors as a veterinarian in India, with high cumulative ultraviolet radiation
exposure. He then moved to the United Kingdom and worked indoors as a pathologist until his retirement. He developed melanoma in situ on his left cheek at
age 46 years and since then has developed 8 melanomas and >20 nonmelanoma skin cancers. He underwent a left hemicolectomy for a sigmoid colon
adenocarcinoma Dukes B at age 55 years, followed by further surgery for mucinous adenocarcinoma Dukes B2 the following year. He subsequently developed
keratoacanthomas and a sebaceous adenoma, leading to a diagnosis of Muir-Torre syndrome [mutation c.306G>T inMLH-1 (Thompson et al., 2014)] unrelated
to his mutation in the XPA gene. (i) Origins of the eight families with mild XP-A are indicated on the map. (j) Immunoblots of protein extracts probed with
monoclonal antibody to XPA protein (BD Bioscience, Oxford, UK, #556453). Left: Calibration: The 50-mg protein extract is made up of the indicated quantities
from normal 48BR cells and XPA-null XP15BR cells. Right: The 50 mg of extract from the indicated cells. The positions of the 50-kDa and 37-kDa markers are
indicated between the panels. XPA protein, indicated with arrows, runs as two bands on either side of the 37-kDa marker. Normal XPA protein level of 5% is
detected in the mild XP-A cases but not in XP15BR. (k) UDS measured by incorporation of 3H-thymidine into nondividing cells after ultraviolet-C irradiation
with the indicated doses. From 5% to 15% of normal UDS is detected in cells from the mild XP-A patients but is undetectable in XP15BR. UDS, unscheduled
DNA synthesis. All patients pictured here have provided written and oral consent for publication of these photographs.
M Sethi et al.
XP Complementation Group A with a Mild Phenotype2010). Their milder phenotype was
attributed to frameshift mutations in
exon 6 [c.689dupT p.(Arg231fs) in
one patient and c.779delCinsTTCTT
p.(Thr260fs) in the other three] resulting
in truncated XPA proteins.
This study highlights the importance
of genotype-phenotype correlations in
XP, not only for diagnosis but also
for prognosis and genetic counseling.
Here we present 12 XP-A patients
with variable sunburn reactions and
normal cognitive and neurologicalphenotype, the largest number of
mild XP-A patients reported to date.
Although the milder skin phenotype
may be related to some extent to the
more pigmented Fitzpatrick skin types,
in our cohort of patients, homozygous
for c.555þ8A>G, we are now able to
give cautiously optimistic prognostic
information with regard to lack of
neurodegeneration and later onset of
skin cancer. A diagnosis of mild XP-A
should be considered in individuals
with facial lentigines, originating fromthe borders of Northern India,
Pakistan, and Afghanistan, as early
photoprotection can reduce further
development of lentigines and poten-
tial skin cancers. Our findings from a
relatively small immigrant population
in the United Kingdom imply that
there may be many such individuals
in the area of origin, who are likely to
be undiagnosed because of the mild-
ness of symptoms and who may suffer
from excessive skin damage later in
life.www.jidonline.org 871
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Dystrophic epidermolysis bullosa (DEB)
is a rare and severe genetic skin disease
inherited in a dominant (DDEB) or
recessive (RDEB) manner, responsible
for blistering of the skin and mucosaafter mild trauma (Bruckner-Tuderman,
2010; Uitto et al., 1992). DEB is
caused by a wide variety of mutations
in COL7A1 encoding type VII collagen,
the major component of anchoring
fibrils which form key attachmentstructures for dermal-epidermal adhe-
sion (Hovnanian et al., 1997; Varki
et al., 2007).
Gene correction approaches based on
sequence-specific DNA double strand
breaks (DSB)-mediated homology-
directed repair (HDR) allow precise
and accurate correction of mutations
(Yanez-Munoz et al., 2006). They have
the potential to restore stable expression
and function of the defective gene and
to reverse the disease phenotype
